Background: With adequate blood transfusion and iron chelation, thalassemia patients have a longer life expectancy and experience long-term metabolic complications, including osteoporosis, fractures, and bone pain. Alendronate, an oral bisphosphonate, is currently used to treat various types of osteoporosis. However, the efficacy for the treatment of thalassemia-associated osteoporosis remains unclear. Methods: We conducted a randomized controlled trial to evaluate the efficacy of alendronate for the treatment of osteoporosis in thalassemia patients. Patients were included if they were males (18–50 years) or premenopausal females with low bone mineral density (BMD) (Z-score
CITATION STYLE
Piriyakhuntorn, P., Tantiworawit, A., Phimphilai, M., Srichairatanakool, S., Teeyasoontranon, W., Rattanathammethee, T., … Charoenkwan, P. (2023). The efficacy of alendronate for the treatment of thalassemia-associated osteoporosis: a randomized controlled trial. Frontiers in Endocrinology, 14. https://doi.org/10.3389/fendo.2023.1178761
Mendeley helps you to discover research relevant for your work.